Generated by AI
XTL Biopharmaceuticals Ltd. ADR is a biopharmaceutical company focused on acquiring and developing pharmaceutical products for autoimmune diseases and other unmet medical needs. Its current product development efforts center on hCDR1, a peptide candidate being studied for systemic lupus erythematosus and Sjögren’s syndrome, and recombinant human erythropoietin (rHuEPO), which is being developed for use in multiple myeloma. The company works through clinical-stage research, licensing arrangements, and product development activities aimed at advancing specialty therapies with targeted mechanisms of action. XTL Biopharmaceuticals Ltd. ADR plays a niche role in the healthcare market as a developer of experimental drug candidates addressing complex conditions where treatment options remain limited.
Website85 Medinat Hayehudim St.
Herzliya, 4676670
Israel
Summary of Jul 1's posts. Generated by AI.
Summary of Jul 1's posts. Generated by AI.
Summary of Apr 29's posts. Generated by AI.
Summary of Jul 1's posts. Generated by AI.
Investors talking about XTLB also mention these. Each card shows that asset’s own numbers for the past 24 hours.